DPP4 and atrial fibrillation: In this nationwide population-based cohort study, we found that SGLT2 inhibitors were associated with a lower risk of the composite outcome of hospitalization for HF or mortality compared to DPP4 inhibitors in patients with both type 2 diabetes and AF.